At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Investors
 



Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Jul 29, 2015
Amicus Therapeutics to Announce Second Quarter 2015 Financial Results on August 5, 2015

Jun 29, 2015
Amicus Therapeutics Joins Russell 3000(R) and Russell 2000(R) Indexes

View all »Events & Presentations

Aug 5, 2015 at 5:00 PM ET
Amicus 2Q Results Conference Call and Webcast

May 5, 2015 at 5:00 PM ET
Amicus 1Q Results Conference Call and Webcast


Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy